Zofra

Zofra

Oral Solution

🧬 Ondansetron 🏢 Eskayef Pharmaceuticals Ltd.
Generic Name Ondansetron
Manufacturer Eskayef Pharmaceuticals Ltd.
Unit Price 50 ml bottle: ৳ 50.00

🔹 Indications

Zofra is a serotonin subtype 3 (5-HT3) receptor antagonist indicated:
  • Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.
  • Prevention and treatment of post-operative nausea and vomiting.
  • Prevention of radiotherapy-induced nausea and vomiting.

🔹 Pharmacology

Zofra is a serotonin subtype 3 (5-HT3) receptor antagonist indicated:
  • Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.
  • Prevention and treatment of post-operative nausea and vomiting.
  • Prevention of radiotherapy-induced nausea and vomiting.

🔹 Dosage & Administration

Zofra is a serotonin subtype 3 (5-HT3) receptor antagonist indicated:
  • Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.
  • Prevention and treatment of post-operative nausea and vomiting.
  • Prevention of radiotherapy-induced nausea and vomiting.

🔹 Interaction

Zofra is a serotonin subtype 3 (5-HT3) receptor antagonist indicated:
  • Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.
  • Prevention and treatment of post-operative nausea and vomiting.
  • Prevention of radiotherapy-induced nausea and vomiting.

🔹 Contraindications

Zofra is a serotonin subtype 3 (5-HT3) receptor antagonist indicated:
  • Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.
  • Prevention and treatment of post-operative nausea and vomiting.
  • Prevention of radiotherapy-induced nausea and vomiting.

🔹 Side Effects

Zofra is a serotonin subtype 3 (5-HT3) receptor antagonist indicated:
  • Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.
  • Prevention and treatment of post-operative nausea and vomiting.
  • Prevention of radiotherapy-induced nausea and vomiting.

🔹 Pregnancy & Lactation

Zofra is a serotonin subtype 3 (5-HT3) receptor antagonist indicated:
  • Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.
  • Prevention and treatment of post-operative nausea and vomiting.
  • Prevention of radiotherapy-induced nausea and vomiting.

🔹 Precautions & Warnings

Zofra is a serotonin subtype 3 (5-HT3) receptor antagonist indicated:
  • Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.
  • Prevention and treatment of post-operative nausea and vomiting.
  • Prevention of radiotherapy-induced nausea and vomiting.

🔹 Pediatric Usage

Zofra is a serotonin subtype 3 (5-HT3) receptor antagonist indicated:
  • Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.
  • Prevention and treatment of post-operative nausea and vomiting.
  • Prevention of radiotherapy-induced nausea and vomiting.

🔹 Storage Conditions

Zofra is a serotonin subtype 3 (5-HT3) receptor antagonist indicated:
  • Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.
  • Prevention and treatment of post-operative nausea and vomiting.
  • Prevention of radiotherapy-induced nausea and vomiting.

💡 Frequently Asked Questions

Zofra is a serotonin subtype 3 (5-HT3) receptor antagonist indicated: Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. Prevention and treatment of post-operative nausea and vomiting. Pre...
Zofra is a serotonin subtype 3 (5-HT3) receptor antagonist indicated: Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. Prevention and treatment of post-operative nausea and vomiting. Pre...
Zofra is a serotonin subtype 3 (5-HT3) receptor antagonist indicated: Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. Prevention and treatment of post-operative nausea and vomiting. Pre...

User Reviews

No reviews yet!
Be the first to share your experience.

Write a Review